KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash from Operations (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Cash from Operations data on record, last reported at 19069000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 37.78% year-over-year to 19069000.0; the TTM value through Dec 2025 reached 111209000.0, up 46.03%, while the annual FY2025 figure was 111209000.0, 46.03% up from the prior year.
  • Cash from Operations reached 19069000.0 in Q4 2025 per PACB's latest filing, down from 18707000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 15712000.0 in Q2 2021 and bottomed at 94691000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 47541550.0, with a median of 44759500.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: plummeted 285.46% in 2022, then skyrocketed 58.85% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 31708000.0 in 2021, then tumbled by 91.01% to 60566000.0 in 2022, then grew by 4.96% to 57560000.0 in 2023, then skyrocketed by 46.75% to 30650000.0 in 2024, then skyrocketed by 37.78% to 19069000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 19069000.0 in Q4 2025, 18707000.0 in Q3 2025, and 29377000.0 in Q2 2025.